Zvirych V. Optimization of combined treatment for locally advanced distal rectal cancer considering prognostic factors

This prospective randomized controlled trial is based on the treatment results from 110 patients with local advanced rectal cancer (LARC). The aim of our study was to define the factors that can robustly predict a response to neoadjuvant chemoradiotherapy (NCRT) in patients with local advanced rectal cancer (LARC) and prognosis factors of progression free survival (PFS) using molecular (8-oxo-dGuо), immunohystochemical (Ki-67) and genetic (GSTP1 and MTHFR genes polymorphism) markers. Patients from main group (MG) underwent radiotherapy with total radiation dose of 50,4 Gy (28 sessions 1,8 Gy each) and polychemotherapy according to СAPOX regimen with oxaliplatin in neoadjuvant regime: capecitabine 2000 µg/m2, patients from control group (CG) underwent radiotherapy with total radiation dose of 50,4 Gy (28 sessions 1,8 Gy each) and monochemotherapy based on fluoropyrimidines in neoadjuvant regime: capecitabine 2000 µg/m2 peroral twice a day.